[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609545":3},{"organization":4,"outcomesModule":7,"designInfo":74,"detailedDescription":11,"studyPopulation":77,"armGroups":78,"interventions":83,"overallOfficials":89,"centralContacts":93,"locations":101,"responsibleParty":260,"collaborators":11,"id":262,"slug":263,"hasResults":264,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":11,"eligibilityCriteria":268,"healthyVolunteers":264,"sex":269,"minAge":270,"maxAge":11,"enrollmentInfo":271,"targetDuration":11,"studyType":274,"phases":11,"briefSummary":275,"conditions":276,"keywords":278,"overallStatus":139,"whyStopped":11,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":289},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":15,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Change in transfusion burden",null,"Baseline and up to week 144",{"measure":14,"description":11,"timeFrame":12},"Change in mean pre-transfusion hemoglobin level",[16,18,20,22,24,26,28,31,33,35,37,39,41,43,45,47,49,52,54,56,59,62,65,68,70,72],{"measure":17,"description":11,"timeFrame":12},"Change in transfusion-related visits",{"measure":19,"description":11,"timeFrame":12},"Proportion of participants achieving ≥33% reduction in red blood cell (RBC) transfusion burden (number of RBC units transfused) plus a reduction of ≥2 units",{"measure":21,"description":11,"timeFrame":12},"Proportion of participants achieving ≥50% reduction in red blood cell transfusion burden plus a reduction of ≥2 units",{"measure":23,"description":11,"timeFrame":12},"Time from first luspatercept dosing date to the first erythroid response",{"measure":25,"description":11,"timeFrame":12},"Time from the date the erythroid response is first observed until the last day of response",{"measure":27,"description":11,"timeFrame":12},"Participant pretransfusion hemoglobin level",{"measure":29,"description":11,"timeFrame":30},"Participant baseline transfusion burden","Baseline",{"measure":32,"description":11,"timeFrame":12},"Proportion of participants without red blood cell transfusion during any consecutive 12-week or 24-week treatment period",{"measure":34,"description":11,"timeFrame":12},"Time from first luspatercept dosing date to first onset of red blood cell-transfusion independence ≥12 weeks and ≥24 weeks",{"measure":36,"description":11,"timeFrame":12},"Time from the date a 12-week and 24-week red blood cell-transfusion independence is first observed until the date the participant has a subsequently documented red blood cell transfusion",{"measure":38,"description":11,"timeFrame":12},"Change in mean serum ferritin (SF) level",{"measure":40,"description":11,"timeFrame":12},"Change in proportion of participants with mean serum ferritin \u003C1,000, 1000-2500, and >2,500 μg\u002FL",{"measure":42,"description":11,"timeFrame":12},"Types (drug formulation - mono and combination therapy) of iron chelation therapy received",{"measure":44,"description":11,"timeFrame":12},"Change in mean daily dose of iron chelation therapy from baseline",{"measure":46,"description":11,"timeFrame":12},"Number of medical encounters (inpatient hospitalizations, emergency department attendances, hospital outpatient visits, visits at office-based physicians)",{"measure":48,"description":11,"timeFrame":12},"Inpatient length of stay",{"measure":50,"description":11,"timeFrame":51},"Proportion of participants remaining on luspatercept treatment","Up to week 144",{"measure":53,"description":11,"timeFrame":51},"Length of time from initiation to discontinuation of luspatercept treatment",{"measure":55,"description":11,"timeFrame":51},"Frequencies of reasons for discontinuation of luspatercept treatment",{"measure":57,"description":58,"timeFrame":30},"Participant sociodemographics","Sociodemographics of participants such as age, sex, ethnicity, country of treatment, height, weight, and body mass index",{"measure":60,"description":61,"timeFrame":30},"Participant disease characteristics","Disease characteristics of participants, describing age of diagnosis of β-thalassemia, genotype (β0\u002Fβ0, non-β0\u002Fβ0), splenectomy status (yes\u002Fno), pretransfusion hemoglobin level (mean of all documented), transfusion burden (total number of red blood cell units transfused).",{"measure":63,"description":64,"timeFrame":30},"Participant comorbidities","Disease- and non-disease-related comorbid conditions",{"measure":66,"description":67,"timeFrame":30},"Concomitant treatment(s) received","Disease-related best supportive care (BSC) and treatments for other comorbidities.",{"measure":69,"description":11,"timeFrame":51},"Number of luspatercept doses administered",{"measure":71,"description":11,"timeFrame":51},"Number of luspatercept dose modifications",{"measure":73,"description":11,"timeFrame":51},"Frequencies of reasons for luspatercept dose modifications",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":75,"timePerspective":76,"maskingInfo":11},"COHORT","OTHER","The study population will include adult patients with transfusion-dependent β-thalassemia (TDT) in the Middle East region who have initiated luspatercept treatment",[79],{"label":80,"type":11,"description":11,"interventionNames":81},"Participants receiving luspatercept treatment",[82],"Drug: Luspatercept",[84],{"type":85,"name":86,"description":87,"armGroupLabels":88,"otherNames":11},"DRUG","Luspatercept","According to the product label",[80],[90],{"name":91,"affiliation":5,"role":92},"Bristol Myers Squibb","STUDY_DIRECTOR",[94,99],{"name":95,"role":96,"phone":97,"phoneExt":11,"email":98},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":100,"role":96,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[102,118,125,137,153,162,174,186,198,210,223,239,251],{"facility":103,"status":104,"city":105,"state":11,"zip":106,"country":107,"countryCode":108,"cosmosGeoPoint":109,"geoPoint":114,"contacts":115},"Local Institution - 202","NOT_YET_RECRUITING","Al Jahra","00020","Kuwait","KW",{"type":110,"coordinates":111},"Point",[112,113],47.65806,29.3375,{"lat":113,"lon":112},[116],{"name":117,"role":96,"phone":11,"phoneExt":11,"email":11},"Site 202",{"facility":119,"status":104,"city":120,"state":11,"zip":121,"country":107,"countryCode":108,"cosmosGeoPoint":11,"geoPoint":11,"contacts":122},"Local Institution - 201","Andalusia","70050",[123],{"name":124,"role":96,"phone":11,"phoneExt":11,"email":11},"Site 201",{"facility":126,"status":104,"city":127,"state":11,"zip":128,"country":107,"countryCode":108,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Local Institution - 203","Kuwait City","20001",{"type":110,"coordinates":130},[131,132],47.97429,29.367,{"lat":132,"lon":131},[135],{"name":136,"role":96,"phone":11,"phoneExt":11,"email":11},"Site 203",{"facility":138,"status":139,"city":140,"state":141,"zip":142,"country":143,"countryCode":144,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"Sultan Qaboos University Hospital","RECRUITING","Seeb","Muḩāfaz̧at Masqaţ","123","Oman","OM",{"type":110,"coordinates":146},[147,148],58.18911,23.67027,{"lat":148,"lon":147},[151],{"name":152,"role":96,"phone":11,"phoneExt":11,"email":11},"Salam Al Kindi, Site 301",{"facility":154,"status":104,"city":155,"state":11,"zip":156,"country":157,"countryCode":158,"cosmosGeoPoint":11,"geoPoint":11,"contacts":159},"Local Institution - 109","Al Hofuf and Al Mubarraz","36422","Saudi Arabia","SA",[160],{"name":161,"role":96,"phone":11,"phoneExt":11,"email":11},"Site 109",{"facility":163,"status":139,"city":164,"state":11,"zip":165,"country":157,"countryCode":158,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"Prince Mohammed Bin Fahad Hospital","Al Qaţīf","32654",{"type":110,"coordinates":167},[168,169],50.0089,26.56542,{"lat":169,"lon":168},[172],{"name":173,"role":96,"phone":11,"phoneExt":11,"email":11},"Abdullah H. Al Zayed, Site 103",{"facility":175,"status":104,"city":176,"state":11,"zip":177,"country":157,"countryCode":158,"cosmosGeoPoint":178,"geoPoint":182,"contacts":183},"Local Institution - 106","Dammam","32263",{"type":110,"coordinates":179},[180,181],50.10326,26.43442,{"lat":181,"lon":180},[184],{"name":185,"role":96,"phone":11,"phoneExt":11,"email":11},"Site 106",{"facility":187,"status":104,"city":188,"state":11,"zip":189,"country":157,"countryCode":158,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Local Institution - 102","Jizan","82943",{"type":110,"coordinates":191},[192,193],42.55111,16.88917,{"lat":193,"lon":192},[196],{"name":197,"role":96,"phone":11,"phoneExt":11,"email":11},"Site 102",{"facility":199,"status":104,"city":200,"state":11,"zip":201,"country":157,"countryCode":158,"cosmosGeoPoint":202,"geoPoint":206,"contacts":207},"Local Institution - 105","Mecca","24241",{"type":110,"coordinates":203},[204,205],39.82563,21.42664,{"lat":205,"lon":204},[208],{"name":209,"role":96,"phone":11,"phoneExt":11,"email":11},"Site 105",{"facility":211,"status":139,"city":212,"state":11,"zip":213,"country":157,"countryCode":158,"cosmosGeoPoint":214,"geoPoint":218,"contacts":219},"King Saud Medical Complex","Riyadh","12746",{"type":110,"coordinates":215},[216,217],46.72185,24.68773,{"lat":217,"lon":216},[220],{"name":221,"role":96,"phone":222,"phoneExt":11,"email":11},"Aleem Aamer, Site 101","+966502021897",{"facility":224,"status":139,"city":225,"state":226,"zip":227,"country":228,"countryCode":229,"cosmosGeoPoint":230,"geoPoint":234,"contacts":235},"Sheikh Shakhbout Medical City (SSMC)","Abu Dhabi","Abu Dhabi Emirate","11001","United Arab Emirates","AE",{"type":110,"coordinates":231},[232,233],54.39696,24.45118,{"lat":233,"lon":232},[236],{"name":237,"role":96,"phone":238,"phoneExt":11,"email":11},"Hussni Al Hateeti, Site 502","00971507160033",{"facility":240,"status":104,"city":241,"state":226,"zip":242,"country":228,"countryCode":229,"cosmosGeoPoint":243,"geoPoint":247,"contacts":248},"Local Institution - 503","Al Ain City","15258",{"type":110,"coordinates":244},[245,246],55.76056,24.19167,{"lat":246,"lon":245},[249],{"name":250,"role":96,"phone":11,"phoneExt":11,"email":11},"Site 503",{"facility":252,"status":104,"city":225,"state":11,"zip":253,"country":228,"countryCode":229,"cosmosGeoPoint":254,"geoPoint":256,"contacts":257},"Local Institution - 501","0",{"type":110,"coordinates":255},[232,233],{"lat":233,"lon":232},[258],{"name":259,"role":96,"phone":11,"phoneExt":11,"email":11},"Site 501",{"type":261,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100609545","a-real-world-study-to-evaluate-luspatercept-in-adults-with-transfusion-dependent-beta-thalassemia-in-the-middle-east-100609545",false,"NCT07215975","A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East","REal-World Application of Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East (RELATE): A Non-interventional Retrospective and Prospective Observational Study","Inclusion Criteria:\n\n* Male or female participants of any race aged at least 18 years at time of initiation of luspatercept treatment\n* Participants with documented diagnosis of transfusion-dependent β-thalassemia (TDT).\n* Participants who have been initiated on treatment with luspatercept as per the product's Summary of Product Characteristics (SmPC) no longer than 12 months prior to informed consent signature, and for whom therapy is ongoing.\n* Participants for whom the decision to prescribe luspatercept treatment is clearly separated from the physician's decision to include the participant in the current study.\n* Participants who have provided signed informed consent for participating in the study and for collecting and analyzing medical data pertinent to the objectives of this study\n\nExclusion Criteria:\n\n* Participants that meet any of the contraindications to the administration of luspatercept as outlined in the latest version of the locally approved SmPC.\n* Participants who are currently receiving or are planned to receive treatment with any investigational drug\u002Fdevice\u002Fintervention or who have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) prior to luspatercept therapy initiation.\n* Participants who are currently pregnant, breastfeeding, or planning a pregnancy during the study observation period.\n* Participants who have not provided signed informed consent for participating in the study and for collecting and analysing medical data pertinent to the objectives of this study.","ALL","18 Years",{"count":272,"type":273},200,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle East",[277],"β-thalassemia",[279],"Transfusion-dependent β-thalassemia","2026-08-18",{"date":282,"type":283},"2026-08-19","ACTUAL",{"date":285,"type":283},"2026-06-26",{"date":287,"type":273},"2031-04-17",{"name":5,"class":6},13]